Compare AMPL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | ORIC |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 818 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.7M | 837.3M |
| IPO Year | 2021 | 2020 |
| Metric | AMPL | ORIC |
|---|---|---|
| Price | $6.48 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $13.42 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | N/A |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $14.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $5.51 |
| 52 Week High | $14.27 | $14.93 |
| Indicator | AMPL | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 36.54 |
| Support Level | $6.43 | $7.90 |
| Resistance Level | $7.73 | $11.22 |
| Average True Range (ATR) | 0.42 | 0.44 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 31.95 | 26.18 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.